ReviewBody image2008
Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
Review in Body image, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 211 citations in OpenAlex.
- Prevalence of Body Dysmorphic Disorder: A Systematic Review and Meta-Analysis.Journal of cosmetic dermatology · 2025Pooled it
- Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial.Behavior therapy · 2014Trial
- A prospective pilot study of levetiracetam for body dysmorphic disorder.CNS spectrums · 2009Trial
- Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.International clinical psychopharmacology · 2009Trial
- Body Dysmorphic Disorder: 21st Century Challenges.International journal of dermatology · 2025Review
- Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I.Journal of psychopharmacology (Oxford, England) · 2024Review
- A review of psychocutaneous disorders from a psychotherapeutic perspective-Toolkit for the dermatologist.Skin health and disease · 2023Review
- Body Dysmorphic Disorder Questionnaire-Dermatology Version (BDD-DV): formation and validation of the Polish language version.Postepy dermatologii i alergologii · 2023Article
- Early response to cognitive behavioral therapy for body dysmorphic disorder as a predictor of outcomes.Journal of psychiatric research · 2022Article
- Treatment utilization and treatment barriers in individuals with body dysmorphic disorder.BMC psychiatry · 2020Article
- Etiological factors and treatment challenges in an adolescent male with body dysmorphic disorder: A case report.SAGE open medical case reports · 2020Article
- Awareness and experiences of cosmetic treatment providers with body dysmorphic disorder in Saudi Arabia.PeerJ · 2020Article
- Magnitude and determinants of body dysmorphic disorder among female students in Saudi public secondary schools.Journal of Taibah University Medical Sciences · 2019Article
- Pharmacological Treatment of Body Dysmorphic Disorder.Current neuropharmacology · 2019Review
- New perspectives in the treatment of body dysmorphic disorder.F1000Research · 2018Review
- Obsessive Compulsive and Related Disorders: From the Biological Basis to a Rational Pharmacological Treatment.The international journal of neuropsychopharmacology · 2018Article
- Recent advances in understanding and managing body dysmorphic disorder.Evidence-based mental health · 2017Review
- [Body dysmorphic disorder : Anxiety about deformity].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016Review
- Muscle dysmorphia: current insights.Psychology research and behavior management · 2016Review
- Cued panic attacks in body dysmorphic disorder.Journal of psychiatric practice · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Body dysmorphic disorder (BDD) is a relatively common and often disabling disorder with high morbidity and mortality. Both psychotropic medication and cognitive behavioral therapy (CBT) are considered first-line treatments for BDD, and medication treatment is often essential for more severely ill and suicidal patients. In this practical overview of the pharmacotherapy of BDD, we briefly describe BDD's clinical features, associated morbidity, and how to recognize and diagnose BDD. We describe the importance of forming a therapeutic alliance with the patient, the need for psychoeducation, and other essential groundwork for successful treatment of BDD. We review available pharmacotherapy research, with a focus on serotonin-reuptake inhibitors (SSRIs, or SRIs), which are currently considered the medication of choice for BDD. Many patients have substantial improvement in core BDD symptoms, psychosocial functioning, quality of life, suicidality, and other aspects of BDD when treated with appropriate pharmacotherapy that targets BDD symptoms. We also discuss practical issues such as dosing, length of treatment, and potential side effects associated with the use of SRIs. In addition, we discuss pharmacotherapy approaches that can be tried if SRI treatment alone is not adequately helpful. Finally, some misconceptions about pharmacotherapy, gaps in knowledge about BDD's treatment, and the need for additional research are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.